- Home
- KPRX vs CWD Comparison
KPRX vs CWD Comparison
Compare KPRX & CWD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- KPRX
- CWD
- Stock Information
- Founded
- KPRX 1998
- CWD 2009
- Country
- KPRX United States
- CWD United States
- Employees
- KPRX N/A
- CWD N/A
- Industry
- KPRX Biotechnology: In Vitro & In Vivo Diagnostic Substances
- CWD Real Estate
- Sector
- KPRX Health Care
- CWD Finance
- Exchange
- KPRX Nasdaq
- CWD Nasdaq
- Market Cap
- KPRX 12.0M
- CWD 12.1M
- IPO Year
- KPRX N/A
- CWD 2023
- Fundamental
- Price
- KPRX $3.47
- CWD $0.62
- Analyst Decision
- KPRX Strong Buy
- CWD
- Analyst Count
- KPRX 1
- CWD 0
- Target Price
- KPRX $10.00
- CWD N/A
- AVG Volume (30 Days)
- KPRX 46.3K
- CWD 37.7K
- Earning Date
- KPRX 03-24-2025
- CWD 03-20-2025
- Dividend Yield
- KPRX N/A
- CWD N/A
- EPS Growth
- KPRX N/A
- CWD N/A
- EPS
- KPRX 1.69
- CWD N/A
- Revenue
- KPRX $16,020,000.00
- CWD $66,376,999.00
- Revenue This Year
- KPRX N/A
- CWD N/A
- Revenue Next Year
- KPRX N/A
- CWD $38.91
- P/E Ratio
- KPRX $2.05
- CWD N/A
- Revenue Growth
- KPRX N/A
- CWD N/A
- 52 Week Low
- KPRX $3.00
- CWD $0.37
- 52 Week High
- KPRX $6.75
- CWD $1.20
- Technical
- Relative Strength Index (RSI)
- KPRX 44.69
- CWD 51.12
- Support Level
- KPRX $3.40
- CWD $0.58
- Resistance Level
- KPRX $3.75
- CWD $0.68
- Average True Range (ATR)
- KPRX 0.22
- CWD 0.06
- MACD
- KPRX -0.03
- CWD 0.00
- Stochastic Oscillator
- KPRX 37.65
- CWD 65.00
About KPRX Kiora Pharmaceuticals Inc.
Kiora Pharmaceuticals Inc is a clinical-stage biotechnology company developing and commercializing products for the treatment of orphan retinal diseases. As part of its development, KIO-301 is being studied for the treatment of retinitis pigmentosa, choroideremia, and Stargardt disease. It is a molecular photoswitch that has the potential to restore vision in patients with inherited and/or age-related retinal degeneration. KIO-104 is being developed for the treatment of posterior non-infectious uveitis. It is a next-generation, non-steroidal, immuno-modulatory, and small-molecule inhibitor of dihydroorotate dehydrogenase.
About CWD CaliberCos Inc.
CaliberCos Inc is an asset management firm, whose primary goal is to enhance the wealth of investors seeking to make investments in middle-market assets. The company's funds include investment vehicles focused on real estate, private equity, and debt facilities. The company earns asset management fees calculated as a percentage of managed capital in funds and offerings. The company markets services through direct sales to private investors, wholesaling to investment advisers, direct sales to family offices and institutions and through in-house client services. The company operates into three reportable segments: Fund Management, Development, and Brokerage. Majority of revenue is derived from Asset management fees segment.